NLS Pharmaceutics Announces Promising Preclinical Results for Parkinson's Disease TreatmentsAccesswire • 06/27/24
Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing RequirementsAccesswire • 06/25/24
NLS Pharmaceutics Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (DOXA)Accesswire • 06/11/24
NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request HearingAccesswire • 04/19/24
NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist PlatformAccesswire • 03/20/24
NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.Accesswire • 12/01/23
NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive into Narcolepsy and Idiopathic HypersomniaAccesswire • 11/27/23
NLS Pharmaceutics Announces Selection of Strategic Partner and Securing a Bridge LoanAccesswire • 11/16/23